Literature DB >> 22072239

Diagnostic accuracy of ¹⁸F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis.

Giorgio Treglia1, Marco Salsano, Antonella Stefanelli, Maria Vittoria Mattoli, Alessandro Giordano, Lorenzo Bonomo.   

Abstract

OBJECTIVE: To systematically review and meta-analyse literature data on the diagnostic performance of fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) in patients with Ewing sarcoma family tumours (ESFT).
MATERIALS AND METHODS: PubMed/MEDLINE, Embase and Scopus databases were searched for articles that evaluated FDG-PET and PET/CT in patients with ESFT from inception to 31 May 2011. Studies that fulfilled the three following criteria were included in the systematic review: FDG-PET or PET/CT performed in patients with ESFT; articles about the diagnostic accuracy of FDG-PET and PET/CT; sample size of at least 10 patients with ESFT were included. Studies in which there were sufficient data to reassess sensitivity and specificity of FDG-PET or PET/CT in ESFT were included in the meta-analysis, excluding duplicate publications. Finally, pooled sensitivity, pooled specificity and area under the receiver operating characteristic (ROC) curve of FDG-PET or PET/CT in ESFT were calculated.
RESULTS: We found 13 studies comprising a total of 342 patients with ESFT. The main findings of the studies included are presented. The meta-analysis of five selected studies provided these results about FDG-PET and PET/CT in ESFT: pooled sensitivity: 96% (95% confidence interval [CI] 91-99%); pooled specificity: 92% (95% CI 87-96%); area under the ROC curve: 0.97.
CONCLUSION: With regard to the staging and restaging of patients with ESFT, the sensitivity, specificity and accuracy of FDG-PET and PET/CT are high; the combination of FDG-PET or PET/CT with conventional imaging is a valuable tool for the staging and restaging of ESFT and has a relevant impact on the treatment strategy plan.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072239     DOI: 10.1007/s00256-011-1298-9

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  17 in total

1.  FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT.

Authors:  C Franzius; H E Daldrup-Link; J Sciuk; E J Rummeny; S Bielack; H Jürgens; O Schober
Journal:  Ann Oncol       Date:  2001-04       Impact factor: 32.976

2.  Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET.

Authors:  H E Daldrup-Link; C Franzius; T M Link; D Laukamp; J Sciuk; H Jürgens; O Schober; E J Rummeny
Journal:  AJR Am J Roentgenol       Date:  2001-07       Impact factor: 3.959

Review 3.  PET/CT in primary musculoskeletal tumours: a step forward.

Authors:  A Lakkaraju; C N Patel; K M Bradley; A F Scarsbrook
Journal:  Eur Radiol       Date:  2010-06-25       Impact factor: 5.315

Review 4.  PET/CT in the evaluation of childhood sarcomas.

Authors:  M Beth McCarville; Ryan Christie; Najat C Daw; Sheri L Spunt; Sue C Kaste
Journal:  AJR Am J Roentgenol       Date:  2005-04       Impact factor: 3.959

5.  FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging.

Authors:  C Franzius; H E Daldrup-Link; A Wagner-Bohn; J Sciuk; W L Heindel; H Jürgens; O Schober
Journal:  Ann Oncol       Date:  2002-01       Impact factor: 32.976

6.  FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy.

Authors:  C Franzius; J Sciuk; H E Daldrup-Link; H Jürgens; O Schober
Journal:  Eur J Nucl Med       Date:  2000-09

7.  FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases.

Authors:  Mathieu Charest; Marc Hickeson; Robert Lisbona; Javier-A Novales-Diaz; Vilma Derbekyan; Robert E Turcotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

8.  Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging.

Authors:  Ukihide Tateishi; Umio Yamaguchi; Kunihiko Seki; Takashi Terauchi; Yasuaki Arai; E Edmund Kim
Journal:  Radiology       Date:  2007-12       Impact factor: 11.105

9.  Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors.

Authors:  Hans U Gerth; Kai U Juergens; Uta Dirksen; Joachim Gerss; Otmar Schober; Christiane Franzius
Journal:  J Nucl Med       Date:  2007-11-15       Impact factor: 10.057

10.  Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.

Authors:  Thomas Völker; Timm Denecke; Ingo Steffen; Daniel Misch; Stefan Schönberger; Michail Plotkin; Juri Ruf; Christian Furth; Brigitte Stöver; Hubertus Hautzel; Günter Henze; Holger Amthauer
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544

View more
  26 in total

1.  Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma.

Authors:  A Raciborska; K Bilska; K Drabko; E Michalak; R Chaber; M Pogorzała; K Połczyńska; G Sobol; M Wieczorek; K Muszyńska-Rosłan; M Rychlowska-Pruszyńska; C Rodriguez-Galindo; M Dziuk
Journal:  Clin Transl Oncol       Date:  2015-08-07       Impact factor: 3.405

Review 2.  2-deoxy-2-((18)F)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology.

Authors:  John Freebody; Eva A Wegner; Monica A Rossleigh
Journal:  World J Radiol       Date:  2014-10-28

3.  Peripheral neuroectodermal tumour of the kidney (Ewing's sarcoma): Restaging with (18)F-fluorodeoxyglucose (FDG)-PET/CT.

Authors:  Hakan Ozturk
Journal:  Can Urol Assoc J       Date:  2015 Jan-Feb       Impact factor: 1.862

4.  Atypical growth on MRI in a case of Ewing's sarcoma despite lower SUV on PET.

Authors:  Zachary Sanford; Stanford Israelsen; Rajesh Sehgal; Felix H Cheung
Journal:  Skeletal Radiol       Date:  2013-12-19       Impact factor: 2.199

Review 5.  Local recurrence of soft-tissue sarcoma: issues in imaging surveillance strategy.

Authors:  Nisreen S Ezuddin; Juan Pretell-Mazzini; Raphael L Yechieli; Darcy A Kerr; Breelyn A Wilky; Ty K Subhawong
Journal:  Skeletal Radiol       Date:  2018-05-21       Impact factor: 2.199

6.  Diagnostic accuracy of 18F-FDG PET/CT for detecting recurrence in patients with primary skeletal Ewing sarcoma.

Authors:  Punit Sharma; Bangkim Chandra Khangembam; K C Sudhir Suman; Harmandeep Singh; Sishir Rastogi; Shah Alam Khan; Sameer Bakhshi; Sanjay Thulkar; Chandrasekhar Bal; Arun Malhotra; Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-05       Impact factor: 9.236

Review 7.  Assessing the role of ¹⁸F-FDG PET and ¹⁸F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: a systematic review and meta-analysis.

Authors:  Elba C Etchebehere; Brian P Hobbs; Denái R Milton; Osama Malawi; Shreyaskumar Patel; Robert S Benjamin; Homer A Macapinlac
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-03       Impact factor: 9.236

Review 8.  The adolescent and young adult with cancer: state of the art -- bone tumors.

Authors:  Nino Rainusso; Lisa L Wang; Jason T Yustein
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

9.  Multimodality imaging features, metastatic pattern and clinical outcome in adult extraskeletal Ewing sarcoma: experience in 26 patients.

Authors:  B S Somarouthu; A B Shinagare; M H Rosenthal; H Tirumani; J L Hornick; N H Ramaiya; S H Tirumani
Journal:  Br J Radiol       Date:  2014-04-15       Impact factor: 3.039

Review 10.  [Postoperative and posttherapeutic changes after primary bone tumors : What's important for radiologists?]

Authors:  T Grieser; I-M Nöbauer-Huhmann
Journal:  Radiologe       Date:  2017-11       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.